In order to test the efficacy of ATLIII on regulation of IDO gene expression, lung cancer cells were pretreated with 100 ng/ml IFN-γ for 12 h following ATLIII treatment at the dosages of 8, 16, and 32 μmol/l for 24 h. The gene discussed is IDO1; the disease is lung carcinoma.